...
首页> 外文期刊>Oncology >Metastatic RCC: moving towards a chronic disease.
【24h】

Metastatic RCC: moving towards a chronic disease.

机译:转移性RCC:迈向慢性病。

获取原文
获取原文并翻译 | 示例
           

摘要

The article by Posadas and Figlin on systemic therapy in advanced renal cell carcinoma (RCC) provides a very interesting and comprehensive review of our current knowledge concerning the treatment of RCC. As stated by the authors, this field has changed dramatically in the past 6 years, with the approval of six new drugs and at least two additional approvals coming in the very near future. However, after reading this article, readers might be somewhat disappointed by the lack of clear-cut recommendations regarding how they should treat specific patients presenting at their clinic.One of the "advancing paradigms" referred to by the title of the review derives principally from the fact that approval has been provided, drug after drug-without, however, any attempt to prioritize the drugs.
机译:Posadas和Figlin发表的有关晚期肾细胞癌(RCC)全身治疗的文章对我们目前有关RCC治疗的知识进行了非常有趣且全面的综述。正如作者所言,在过去的六年中,该领域发生了巨大变化,六种新药的批准,以及在不久的将来至少有两个新的批准。但是,在阅读了这篇文章之后,读者可能会因缺乏明确的建议而感到失望,该建议没有明确地建议他们应该如何治疗在诊所就诊的特定患者。本综述标题所指的“先进范例”主要来自于已提供批准的事实,一个接一个地接一个药物,但没有尝试对药物进行优先排序。

著录项

  • 来源
    《Oncology》 |2012年第3期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号